AI assistant
Senzime Board/Management Information 2021
3198_rns_2021-11-25_27aff2f9-5d86-4eb0-9631-ca81a94632c7.pdf
Board/Management Information
Open in viewerOpens in your device viewer
PRESS RELEASE 25 November 2021 09:00:00 CET
Nomination Committee in Senzime ahead of the 2022 Annual General Meeting
Press release: Uppsala, 25 November 2021. In accordance with the resolution at the Annual General Meeting of Senzime AB (publ) on May 11, 2021, the three largest shareholders on 1 September 2021 have appointed a Nomination Committee for the 2022 Annual General Meeting.
The three largest shareholders in terms of voting rights (considering owner groupings) as of September 1, 2021, are Adam Dahlberg and his family, AB Segulah and Handelsbanken Fonder. They have each appointed a member, as set out below, to form the Senzime Nomination Committee together with the Chairman of the Board.
- Adam Dahlberg (Chairman)
- Gabriel Urwitz, AB Segulah
- Malin Björkmo, Handelsbanken Fonder
- Philip Siberg, Chairman of the Board of Senzime AB (publ)
The shareholders who have appointed members to the Nomination Committee represent approximately 29 percent of the voting rights of all shares in the company. Shareholders who wish to submit proposals to the Nomination Committee may do so by e-mail to [email protected].
For further information, please contact:
Philip Siberg, Chairman of the Board Phone: +46 70 790 67 34, e-mail: [email protected]
Pia Renaudin, CEO Phone: +46 70-813 34 17, e#mail: [email protected]
About Senzime
Senzime develops and markets CE- and FDA cleared patient monitoring systems driven by unique algorithms and sensors to closely monitor patients under anesthesia. TetraGraph is a system that digitally and continuously measures the degree of neuromuscular blockade in the patient. The goal is improved clinical precision and simplified management in healthcare. By preventing complications and enabling healthcare professionals to follow guidelines and drug recommendations, TetraGraph can contribute to shorten hospital stays and lower healthcare costs. The vision is a world without anesthesia related complications, where everyone wakes up safely after surgery. Senzime operates in growing markets that in Europe and the United States are valued in excess of SEK 15 billion. The company's shares are listed on Nasdaq Stockholm's main market (ticker SEZI) since June, 30 2021. www.senzime.com
Attachments
Nomination Committee in Senzime ahead of the 2022 Annual General Meeting